Суроватамиг

Prop. INN (наименование, предложенное ВОЗ)

2892667-02-4

immunoglobulin (H-gamma4_L-kappa)_VH-G4(h-CH2-CH3), anti-[Homo sapiens CD3D (CD3 delta) and CD3E (CD3 epsilon, Leu-4) dimer] and anti-[Homo sapiens CD19 (B lymphocyte surface antigen B4, Leu-12)], Homo sapiens and humanized monoclonal antibody asymetric, bispecific, bivalent;
H-gamma4 heavy chain anti-CD3D/CD3E dimer, Homo sapiens (1-450) [VH (Homo sapiens IGHV3-9*01 (100%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123) -Homo sapiens IGHG4*01 nG4m(a) CH2 L92, G4v5 h P10, G4v4 CH2 A1.3, A1.2, G4v32 CH3 W22 (knob) (CH1 (124-221), hinge 1-12 S10>P (231) (222-233), CH2 F1.3>A (237), L1.2>A (238), L92 (312) (234-343), CH3 T22>W (369) (344-448), CHS (449-450)) (124-450)], (137-214')-disulfide with L-kappa light chain anti-CD3D-CD3E Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-15*01 (100%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')];
VH-G4(h-CH2-CH3) heavy chain anti-CD19, humanized and Homo sapiens (1''-345'') [humanized VH (Homo sapiens IGHV3-7*01 (91.8%) -(IGHD) -IGHJ4*01 (92.9%) W118>R (106''), CDR-IMGT [8.8.9] (26''-33''.51''-58''.97''-105'')) (1''-116'') -Homo sapiens IGHG4*01 h-CH2-CH3, G4v5 h P10, nG4m(a) CH2 L92, G4v4 CH2 A1.3, A1.2, G1v33 CH3 S22, A24, V86 (hole) (hinge 1-12 S10>P (126'') (117''-128''), CH2 F1.3>A (132''), L1.2>A (133''), L92 (207'') (129''-238''), CH3 T22>S (264''), L24>A (266''), Y86>V (305'') (239''-343''), CHS (344’’-345'')) (117''-345'')]; dimer (229-124'':232-127'')-bisdisulfide, produced in a cell line from Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa

Поделиться этой страницей